Xu-Rong Jiang, PhD AstraZeneca

Dr. Xu-Rong Jiang is currently a Director of Quality and Technical, AstraZeneca BioVentures and Global Biologics Operation. Prior to his current responsibility, Dr. Jiang had served as an Associate Director in Analytical Biotechnology at MedImmune since 2008. He headed the Biological Development Group in support of biologics analytical method development for IND filing, GMP testing, technology transfer and process development. Prior to MedImmune, Dr. Jiang was a Principal Scientist in Process & Analytical Sciences at Amgen where his group was responsible for development, qualification, validation of potency assays for biologics development. Prior to Amgen, Dr. Jiang was a Senior Scientist at Geron Corporation focusing on gene and cell therapy, high throughput screening, and regenerative medicine with embryonic stem cells. Dr. Jiang received his Ph.D. degree in Molecular Cell Biology, University of London. He also had an M.D. in Hematology from China Medical University. Dr. Jiang has served at various scientific and professional organizations and committees. He is an Associate Director for CASSS, an International Separation Science Society. He has been a member of Scientific Organizing Committee for CASSS Bioassays since 2011. Dr. Jiang has also served as an organizing committee for the Cell-based Assay Action Program Committee, American Association for Pharmaceutical Scientists. He has published more than 26 journal papers and is an assignee of three U.S. patents. Dr. Jiang has been the President and the Chairman of the Board of Director of the Chinese Biopharmaceutical Association-USA in 2016-2017.